article thumbnail

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

Drug Channels

Each exclusion list now contains about 600 products. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.

Insulin 92
article thumbnail

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars (rerun)

Drug Channels

Each exclusion list now contains about 600 products. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.

Insulin 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps

The Pharma Data

approval of pump use for Lilly’s novel insulin is latest development designed to help people with diabetes manage blood sugar levels. Lyumjev, a novel formulation of insulin lispro developed to speed the absorption of insulin into the bloodstream and reduce A1C levels, was approved by the FDA in June 2020.

Insulin 52
article thumbnail

New Soliqua® data shows improved blood sugar control without weight gain versus premixed insulin

The Pharma Data

New Soliqua ® * data shows improved blood sugar control without weight gain versus premixed insulin. Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin.

Insulin 52
article thumbnail

The Keto Diet: A Beginner’s Guide on Making the Switch to Keto

Pharma Mirror

The keto diet lowers insulin levels and increases your body’s ability to burn fat. The keto diet, also known as a ketogenic diet, is a type of food-based lifestyle that many people adopt. Essential, it lets you eat foods that are very high in fat and low in carbohydrates.

Insulin 130
article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

One of these markets is the insulin market. Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. Currently, more than seven million patients rely on insulin, and that number is growing each year. But, that will soon be changing, due to biosimilars.

Marketing 100
article thumbnail

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions

Drug Channels

Each exclusion list contains 400 to 500 products. Below, I highlight five observations about this year’s lists, including unexplainable differences in how PBMs handle specialty drugs, biosimilars, and insulin. I also offer some thoughts on non-medical switching and what we still don’t know about how exclusions affect patients.

Insulin 94